Table 3. Relationship between hepatitis B virus infection and site-specific cancers in women.

Cancer Site	Number of patients in the pooled cohort		Matched analysis*
	Total	HBsAg+	OR	95% CI	P value
Stomach	5,373	184	0.98	0.79–1.21	0.825
Colon	2,921	118	1.15	0.87–1.52	0.320
Rectum	1,842	68	1.29	0.89–1.88	0.183
Bile duct	1,584	94	1.71	1.16–2.51	0.007
Pancreas	1,499	55	0.93	0.60–1.44	0.739
Esophagus	62	1	0.50	0.05–5.51	0.571
Gallbladder	691	22	1.06	0.55–2.05	0.866
Lung	2,653	122	1.79	1.32–2.44	<0.001
Kidney	674	27	1.16	0.63–2.14	0.640
Bladder	289	6	1.20	0.37–3.93	0.763
Breast	12,487	482	1.16	1.02–1.32	0.033
Cervix	2,370	118	1.49	1.11–2.00	0.007
Uterus	1,102	66	1.69	1.09–2.61	0.019
Ovary	1,048	53	0.67	0.34–1.31	0.240
Brain	2,484	101	1.09	0.82–1.47	0.549
Head and neck	427	18	1.33	0.63–2.82	0.451
Thyroid	9,815	419	1.49	1.28–1.74	<0.001
Skin	245	11	1.83	0.68–4.96	0.232
Hematologic disease	744	37	1.26	0.73–2.18	0.406
Lymphoma	974	83	3.04	1.92–4.82	<0.001
Bone and soft tissue	192	6	2.00	0.50–8.00	0.327

CI = confidence interval; HBsAg = hepatitis B virus surface antigen; OR = odds ratio.

*Controls were matched to cases by age, hypertension, diabetes, alcohol consumption, smoking status, and serum cholesterol level.